Francis Crespo, MD
Interventional Cardiology · Miami, FLNPI 1528060555
Payments from drug & device makers
Across 234 payments — averaging $51.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Impulse Dynamics (USA) Inc.$1K
- Biotronik Inc.$1K
- Abbott$957
- Boston Scientific$821
- Johnson & Johnson$488
- plus $3K from 21 others
What the payments were for
- Food & beverage$11,89398%
- Education$2162%
- Other$510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 68 | $4,180 |
| Impulse Dynamics (USA) Inc. | 12 | $1,246 |
| Biotronik Inc. | 13 | $1,245 |
| Abbott | 10 | $957 |
| Boston Scientific | 8 | $821 |
| Johnson & Johnson | 23 | $488 |
| Novartis | 10 | $394 |
| Pfizer | 18 | $363 |
| E.r. Squibb & Sons, L.L.C. | 13 | $269 |
| Merck | 8 | $268 |
| Actelion Pharmaceuticals US, Inc. | 5 | $255 |
| Bayer | 10 | $227 |
| AstraZeneca | 5 | $217 |
| Amgen | 10 | $201 |
| Inari Medical, Inc. | 2 | $199 |
| Heartflow, Inc. | 3 | $191 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $171 |
| Asahi Intecc USA, Inc. | 2 | $135 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $91 |
| Surmodics, Inc. | 2 | $67 |
| Baxter Healthcare | 1 | $51 |
| Lilly USA, LLC | 2 | $32 |
| Novo Nordisk | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$1,459
- Resolute$1,308
- WATCHMAN FLX$623
- MitraClip$420
- Micra$350
- OPSUMIT$280
- ONYX FRONTIER$263
- ENTRESTO$245
- VERQUVO$225
- Quadra Assura CRT Defibrillator$179
- MyCareLink$172
- AVEIR$167
- AURORA EV-ICD MRI SURESCAN$164
- SYMPLICITY G3$162
- FLOWTRIEVER CATHETER, S$161
- CT THROMBECTOMY SYSTEM KIT$161
- Amplia MRI$155
- FFRct$148
- OPTIMIZER SMART SYSTEM$139
- Cobalt$124
How this compares
$12,159 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $115,504 |
| EntrestoSacubitril/Valsartan | 101 | $100,353 |
| XareltoRivaroxaban | 63 | $50,130 |
| MounjaroTirzepatide | 17 | $19,362 |
| OzempicSemaglutide | 14 | $13,726 |
| VerquvoVericiguat | 16 | $12,306 |
| FarxigaDapagliflozin Propanediol | 12 | $9,468 |
| BrilintaTicagrelor | 17 | $7,489 |
| Ranolazine ErRanolazine | 57 | $4,290 |
| Nifedipine ErNifedipine | 81 | $1,926 |
| Megestrol Acetate | 20 | $1,270 |
| Rosuvastatin Calcium | 49 | $903 |
| Labetalol Hcl | 77 | $785 |
| Atorvastatin Calcium | 101 | $584 |
| Hydralazine Hcl | 72 | $583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $363 | $115,504159 claims |
| NovartisEntresto | $394 | $100,353101 claims |
| Johnson & JohnsonXarelto | $488 | $50,13063 claims |
| Lilly USA, LLCMounjaro | $32 | $19,36217 claims |
| AstraZenecaFarxiga, Brilinta | $217 | $16,95729 claims |
| Novo NordiskOzempic | $21 | $13,72614 claims |
| MerckVerquvo | $268 | $12,30616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Pedro Martinez-ClarkMiami$1.7M
- Rimsky DenisMiami$1.2M
- Eduardo de MarchenaMiami$978K
- Ramon QuesadaMiami$593K
- Mauricio CohenMiami$351K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.